Literature DB >> 11302956

Probiotics in inflamatory bowel disease.

F Shanahan1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11302956      PMCID： PMC1728287          DOI： 10.1136/gut.48.5.609

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  Immunity and probiotics.

Authors:  B Dugas; A Mercenier; I Lenoir-Wijnkoop; C Arnaud; N Dugas; E Postaire
Journal:  Immunol Today       Date:  1999-09

Review 2.  Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents.

Authors:  F Shanahan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-02       Impact factor: 4.052

3.  Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?

Authors:  M Campieri; P Gionchetti
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

Review 4.  Probiotics and inflammatory bowel disease: is there a scientific rationale?

Authors:  F Shanahan
Journal:  Inflamm Bowel Dis       Date:  2000-05       Impact factor: 5.325

5.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Authors:  K L Madsen; J S Doyle; L D Jewell; M M Tavernini; R N Fedorak
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

6.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

7.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

Authors:  B J Rembacken; A M Snelling; P M Hawkey; D M Chalmers; A T Axon
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321
  7 in total
  17 in total

Review 1.  Probiotics in the management and prevention of atopy.

Authors:  John Bienenstock; Ryan E Wiley; G Scott Neigh; Susan Waserman; Paul Keith
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

Review 2.  Intestinal microflora as a therapeutic target in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Atsushi Toyonaga; Michio Sata
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

3.  Compatibility, Cytotoxicity, and Gastrointestinal Tenacity of Bacteriocin-Producing Bacteria Selected for a Consortium Probiotic Formulation to Be Used in Livestock Feed.

Authors:  Mégane Eveno; Patricia Savard; Yanath Belguesmia; Laurent Bazinet; Frédérique Gancel; Djamel Drider; Ismail Fliss
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

4.  A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Fatemeh Rahimi; Behzad Elahi; Saeed Derakhshani; Mohammad Vafaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

Review 5.  Diet therapy for inflammatory bowel diseases: The established and the new.

Authors:  Franziska Durchschein; Wolfgang Petritsch; Heinz F Hammer
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

6.  Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells.

Authors:  Isabelle Ingrassia; Antony Leplingard; Arlette Darfeuille-Michaud
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

7.  Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.

Authors:  Andreas Sturm; Klaus Rilling; Daniel C Baumgart; Konstantinos Gargas; Tay Abou-Ghazalé; Bärbel Raupach; Jana Eckert; Ralf R Schumann; Corinne Enders; Ulrich Sonnenborn; Bertram Wiedenmann; Axel U Dignass
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

8.  The role of bacteria in the pathogenesis of inflammatory bowel disease.

Authors:  Melissa Friswell; Barry Campbell; Jonathan Rhodes
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

9.  Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background.

Authors:  Andre Bleich; John P Sundberg; Anna Smoczek; Reinhard von Wasielewski; Maike F de Buhr; Lydia M Janus; Gwen Julga; Sya N Ukena; Hans-J Hedrich; Florian Gunzer
Journal:  Int J Exp Pathol       Date:  2007-11-13       Impact factor: 1.925

10.  Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice.

Authors:  Y W Chung; J H Choi; T-Y Oh; C S Eun; D S Han
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.